We demonstrate that GH promotes multiple mechanisms of therapy resistance in NSCLC, primarily through the upregulation of ABC transporters and activation of EMT pathway—two key processes known to underlie resistance in various cancers. The gene discussed is GH1; the disease is non-small cell lung carcinoma.